Incidence of mucositis in patients undergoing autologous hematopoietic stem cell transplantation at a single center

Authors

  • Ana Carolina Amaral Perrone PhD student on Health at Federal University of Juiz de Fora and Nurse of the Hematology and Bone Marrow Transplant Service at UFJF University Hospital
  • Clarissa Ferreira Cunha PhD in Sciences. Biomedical at the Hematology and Bone Marrow Transplant Service at UFJF University Hospital
  • Ana Paula da Silva Pinheiro Nurse at UFJF. Scientific initiation scholarship from UFJF
  • Abrahão Elias Hallack Neto Associate Professor at the Department of Clinical Medicine, Medicine Faculty, Federal University of Juiz de Fora. In charge of the Bone Marrow Transplant Service at the University Hospital of the Federal University of Juiz de Fora

DOI:

https://doi.org/10.46765/2675-374X.2020v1n1p41-45

Keywords:

Hematopoietic stem cell transplantation, Mucositis, Risk factors

Abstract

Goal: The aim of this study was to describe the incidence of oral mucositis (OM) in patients undergoing autologous hematopoietic stem cell transplantation (auto-HSCT), relating it to the main clinical factors. Methodology: Descriptive analysis based on a randomized clinical study was conducted with patients undergoing HSCT at the University Hospital of Federal University of Juiz de Fora between January 2018 and June 2019. The World Health Organi­zation oral toxicity scale was used to assess the degree of oral mucositis and adverse events were graded according to the Common Terminology Criteria for Adverse Events (CTCAE) 4.0 version. Results: Thirty-eight patients were evaluated. The incidence of OM and severe oral mucositis (SOM) was 57.9% and 21.0%, respectively. The mean duration of OM was 7.2 ± 2.6 days and the lomustine, etoposide, cytarabine and cyclophosphamide protocol (LEAC) pre­sented the longest mean time 8.1 ± 3.1 days (p-value 0.02). The number of viable CD34+ cells and the onset day of neutropenia were predictors of SOM. Conclusion: The incidence of OM in patients undergoing HSCT was lower than reported in the literature, being more severe in patients who received less CD34+ cells and in patients with early onset of neutropenia.

Downloads

Published

07/06/2020

How to Cite

Perrone, A. C. A., Cunha, C. F., Pinheiro, A. P. da S., & Hallack Neto, A. E. (2020). Incidence of mucositis in patients undergoing autologous hematopoietic stem cell transplantation at a single center. JOURNAL OF BONE MARROW TRANSPLANTATION AND CELLULAR THERAPY, 1(2), 41–45. https://doi.org/10.46765/2675-374X.2020v1n1p41-45

Most read articles by the same author(s)